The Journal for ImmunoTherapy of Cancer (JITC), the official journal of the Society for Immunotherapy of Cancer (SITC), is a leading publication of original research articles, literature reviews, position papers and discussion on all aspects of tumor immunology and cancer immunotherapy–from basic research to clinical application.
To provide JITC readers with a well-rounded view of research in tumor immunology and cancer immunotherapy, JITC editors (view the JITC Editorial Board here) will share a monthly reading list of publications in other journals that have their attention and add value to what readers may find in JITC.
The following articles have been recommended for further reading in the field of cancer immunotherapy by JITC’s Commentary/Editorials Section Editor, Christian M. Capitini, MD.
“Gene Regulatory Programs Conferring Phenotypic Identities to Human NK Cells,” by Patrick L. Collins et al. Cell 2018 Dec 27; 176(1):348-360
While natural killer (NK) cells are known to play an important role in tumor surveillance, there remains a lack of understanding as to how they regulate clinical efficacy through cytotoxicity, IFNy production, homing, proliferation, self-renewal, and memory. Collins et al. presents an integrated analysis of human NK subsets, revealing super-enhancers associated with gene cohorts that may coordinate NK functions and localization. This study provides integrative and single cell analyses, revealing potential developmental relationships between circulating NK cells and implicates a major clinical role for the use of NK cells in cellular therapies, especially those with a memory or adaptive phenotype.
“Anti-NKG2A mAb is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells,” by Pascale Andre et al. Cell 2018 Dec 13; 175(7):1731-1743.e13
While checkpoint immunotherapy has yielded unprecedented results in patients with advanced stage cancers, only a fraction of patients experience a strong response, leading investigators to examine mechanisms of resistance, novel molecular targets and combination therapies. Andre et al. characterizes the first-in-class immune checkpoint inhibitor, monalizumab, which targets NKG2A to promote anti-tumor immunity by enhancing the activities of both T and NK cells. This study demonstrates how NKG2A blockade enhances the anti-tumor immunity mediated by NK and CD8+ T cells when used as both a single agent or in combination with other monoclonal antibodies and highlights the potential of critical immune checkpoints other than PD-1 and CTLA-4.
“CAR T cells targeting B7-H3, a Pan-Cancer Antigen, Demonstrate Potent Preclinical Activity Against Pediatric Solid Tumors and Brain Tumors,” by Robbie G. Majzner et al. Clin Cancer Res 2019 Jan 17
Although chimeric antigen receptor (CAR) T cells have seen great success in treating relapsed pediatric patients with leukemias, lymphomas and localized sarcomas, this has yet to be translated to solid tumors, due in part to a lack of targetable cell surface molecules. Majzner et al. presents pre-clinical data demonstrating significant anti-tumor potential and clear tumor regression following treatment with B7-H3 (CD276) CAR T cells in in vivo models of osteosarcoma, medulloblastoma and Ewing sarcoma. Thus, in detailing a novel CAR directed at B7-H3, a pan-cancer antigen expressed on many pediatric solid tumors, this study provides promising data for early phase clinical trials.
“IL-15 is a component of the inflammatory milieu in the tumor microenvironment promoting antitumor responses,” by Rosa M. Santana Carrero et al. Proc Natl Acad Sci USA 2019 Jan 8; 116(2):599-608
IL-15 is a cytokine that preferentially stimulates CD8+ T cell and NK cell activation, proliferation, and cytolytic activity. While correlative data implicate IL-15 expression within the tumor microenvironment as a critical factor in modulating antitumor responses, the mechanisms regulating IL-15 within tumors are unknown. Carrerro et al. provides evidence that IL-15 is present within the tumor microenvironment, is regulated by inflammatory signals, and importantly, is capable of enhancing tumor regression through a natural mechanism within tumors that works to enhance antitumor responses. This study supports evaluation of systemic treatments with IL-15 or IL-15 analogs as potential cancer therapeutics.
Tel: +1 414 271 2456 | Fax: +1 414 276 3349 | Email: email@example.com